SOMATIC MUTATIONS IDENTIFICATION OF FGFR3 AMONG HCC EGYPTIAN PATIENTS USING NGS.

Autor:	ELFEKY, AHMED M., ElSHAARAWY, A. A., EBIED, M. E., ELHAMSHARY, MANAL O., TALAAT, RANDA M., SAKR, M. A., KHALIFA, M. K., AHMED, E. A., NASR, GHADA M.
Předmět:	SOMATIC mutation EGYPTIANS FIBROBLAST growth factor receptors CIRCULATING tumor DNA NUCLEOTIDE sequencing FATTY liver
Zdroj:	Egyptian Journal of Genetics & Cytology; Jul2022, Vol. 51 Issue 2, p103-118, 16p
Abstrakt:	Keywords: Hepatocellular carcinoma; Next generation sequencing; fibroblast growth factor receptor 3 EN Hepatocellular carcinoma Next generation sequencing fibroblast growth factor receptor 3 Hepatocellular carcinoma (HCC) isthe most prominent liver cancer,accounting for 85% of primary liver malignancies.It is a very aggressive tumor, havinga terrible prognosis and poor survivalrate (Mir et al., 2021). Six patients had nomutations in the FGFR3 gene: two patients(33.3%) were staged A, two patients(33.3%) were stage B, and two patients(33.3%) were stages C&D (Fig. GLO:lf9p/01jul22:113n1.jpg TABLE: Table (2): Correlation of clinicopathologicalfeatures and mutations of FGFR3 in HCC patients gl Table (2): Correlation of clinicopathologicalfeatures and mutations of FGFR3 in HCC patients FGFR3p-valueNo(n = 6)Yes(n = 15)No. Also a study conducted by(He et al., 2019) who analyzed the correlationbetween the MAFs of specific genesin plasma cfDNA and the tumor load andfound that the MAF values for TP53, RET,APC, and FGFR3 were significantly higherin patients with multiple tumors or HCCwith tumor metastasis than those with asingle tumor HCC. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.